Brief: Cue Health To Develop Omicron-Genotyping Covid-19 Test In Partnership With The U.S. Department Of Health And Human Services' Biomedical Advanced Research And Development Authority (Barda)
06/01/2022 14:18
Jan 6 (Reuters) - Cue Health Inc HLTH.O :
* CUE HEALTH TO DEVELOP OMICRON-GENOTYPING COVID-19 TEST IN
PARTNERSHIP WITH THE U.S. DEPARTMENT OF HEALTH AND HUMAN
SERVICES' BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY
(BARDA)
Source text for Eikon: ID:nPnbzc9Y2a
Further company coverage: HLTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cue Health
See all newsNASDAQ RESUMED AT 09:40 AM
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 AM
U.S. STOCKS ON THE MOVE-Salesforce, Birkenstock, Kohls Corp
U.S. STOCKS ON THE MOVE-Marathon Oil, Faraday Future, Semler Scientific
Brief: Cue Health Inc On May 16, Terminated Its Loan And Security Agreement, Dated June 30, 2022